Views & Analysis 7 questions: Bayer's Eugene Borukhovich Eugene Borukhovich's perspective on digital health and its future.
News NICE rejects Bayer and Eisai drugs in thyroid cancer Thyroid cancer drugs are available in Scotland and Wales
News Bayer left playing catch-up with BMS after Xarelto failure BMS' rival anticoagulant takes commanding market lead.
News NICE recommends Bayer drug for severe short-sightedness Eylea should be funded in mCNV, says NICE
News Bayer gains first Aliqopa approval in follicular lymphoma Bayer has gained FDA accelerated approval for its follicular lymphoma drug Aliqopa (copanlisib), giving it entry to the haemato-oncology market for the first time.
News Bayer unveils latest funding for digital health start-ups Startups focus on medical adherence, endometriosis, atrial fibrillation, and deep vein thrombosis.
Sales & Marketing Biotech is back, with Craig Ackerman In Philadelphia this month, pharmaphorum spoke with Craig Ackerman, a partner at the Alexander Group, about launches, AI best practices, and more.
Sales & Marketing Sponsored Using AI-driven synthetic personas to take your insights fur... As AI continues to reshape the healthcare landscape, pharma teams are beginning to leverage synthetic personas.
